Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates.
Circulating coxsackievirus A16 (CA16) is a major cause of hand, foot and mouth disease (HFMD) in South-east Asia. At present, there is no vaccine against CA16. Pathogenic animal models that are sensitive to diverse circulating CA16 viruses would be desirable for vaccine development and evaluation. In this study, we isolated and characterized several circulating CA16 viruses from recent HFMD patients. These CA16 viruses currently circulating in humans were highly pathogenic in a newly developed neonatal mouse model; we also observed and analysed the pathogenesis of representative circulating recombinant form CA16 viruses. An inactivated CA16 vaccine candidate, formulated with alum adjuvant and containing submicrogram quantities of viral proteins, protected neonatal mice born to immunized female mice from lethal-dose challenge with a series of CA16 viruses. Further analysis of humoral immunity showed that antibody elicited from both the immunized dams and their pups could neutralize various lethal viruses by a cytopathic effect in vitro. Moreover, viral titres and loads in the tissues of challenged pups in the vaccine group were far lower than those in the control group, and some were undetectable. This lethal-challenge model using pathogenic CA16 viruses and the vaccine candidates that mediated protection in this model could be useful tools for the future development and evaluation of CA16 vaccines.
First Hospital of Jilin University, Institute of Virology and AIDS Research, Changchun, Jilin Province, PR China.
Jingliang
J
Li
First Hospital of Jilin University, Institute of Virology and AIDS Research, Changchun, Jilin Province, PR China.
Junliang
J
Chang
First Hospital of Jilin University, Institute of Virology and AIDS Research, Changchun, Jilin Province, PR China.
Xin
X
Liu
First Hospital of Jilin University, Institute of Virology and AIDS Research, Changchun, Jilin Province, PR China.
Jiaxin
J
Yang
Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD 21205, USA.|First Hospital of Jilin University, Institute of Virology and AIDS Research, Changchun, Jilin Province, PR China.
Haoran
H
Guo
Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD 21205, USA.|First Hospital of Jilin University, Institute of Virology and AIDS Research, Changchun, Jilin Province, PR China.
Wei
W
Wei
First Hospital of Jilin University, Institute of Virology and AIDS Research, Changchun, Jilin Province, PR China.
Wenyan
W
Zhang
Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD 21205, USA.|First Hospital of Jilin University, Institute of Virology and AIDS Research, Changchun, Jilin Province, PR China.
Xiao-Fang
XF
Yu
D000818:Animals; D000831:Animals, Newborn; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D004195:Disease Models, Animal; D004770:Enterovirus / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D005260:Female; D006232:Hand, Foot and Mouth Disease / Q000517:prevention & control* / Q000821:virology; D006801:Humans; D051379:Mice; D008813:Mice, Inbred ICR; D008969:Molecular Sequence Data; D012367:RNA, Viral / Q000235:genetics; D017422:Sequence Analysis, DNA; D016019:Survival Analysis; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D019562:Viral Load; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D012367:RNA, Viral; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic; D014765:Viral Vaccines